Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 71-year-old woman is evaluated via telehealth for dysuria, suprapubic discomfort, and urinary urgency that began 2 days ago. She has a history of a mechanical mitral valve replacement performed 3 years ago, for which she takes chronic warfarin. Her most recent international normalized ratio (INR) checked one week ago was 2.9, which is within her target range of 2.5 to 3.5. She reports no fever, chills, back pain, or gross hematuria. A clean-catch urinalysis obtained at a local laboratory demonstrates positive nitrites, positive leukocyte esterase, and >50 white blood cells per high-power field. The physician diagnoses acute uncomplicated cystitis and plans to prescribe a 3-day course of trimethoprim-sulfamethoxazole.

Which of the following are necessary monitoring and treatment adjustments for this patient? (Select 2 options)

  1. Preemptively reduce the weekly warfarin dose by 25% to 50%Answer
  2. Schedule a repeat international normalized ratio (INR) measurement in 3 to 5 daysAnswer
  3. C
    Maintain the current warfarin dose and recheck the international normalized ratio (INR) 14 days after antibiotic completion
  4. D
    Order a baseline activated partial thromboplastin time (aPTT) prior to initiating the antibiotic
  5. E
    Order a non-contrast head computed tomography (CT) scan to screen for spontaneous intracranial hemorrhage

Answer

Preemptively reduce the weekly warfarin dose by 25% to 50% AND schedule a repeat international normalized ratio (INR) measurement in 3 to 5 days.
Trimethoprim-sulfamethoxazole (TMP-SMX) strongly interacts with warfarin, primarily through the inhibition of the cytochrome P450 2C9 (CYP2C9) enzyme. CYP2C9 is responsible for metabolizing the more potent S-enantiomer of warfarin. Additionally, broad-spectrum antibiotics like TMP-SMX eradicate intestinal flora that produce vitamin K, further enhancing the anticoagulant effect. This synergistic interaction predictably leads to a rapid and clinically significant elevation of the INR, increasing the risk of life-threatening hemorrhage. To safely manage this interaction when concurrent use is unavoidable, the standard of care requires a preemptive reduction of the weekly warfarin dose by 25% to 50%. Because the INR can spike within days of starting the antibiotic, close monitoring is mandatory; checking a repeat INR within 3 to 5 days allows for timely detection of over-anticoagulation and further dose adjustments if necessary.

Step-by-Step Solution

1
Identify the primary pharmacological interaction.
Trimethoprim-sulfamethoxazole inhibits CYP2C9 and depletes vitamin K-producing gut flora, significantly increasing warfarin's anticoagulant effect.
Recognizing drug-drug interactions is critical before prescribing new medications to patients on chronic narrow-therapeutic-index drugs.
2
Determine the necessary dose adjustment.
Reduce the weekly warfarin dose by 25% to 50%.
Preemptive dose reduction mitigates the anticipated supratherapeutic spike in INR and prevents severe bleeding events.
3
Establish the appropriate monitoring interval.
Check the INR within 3 to 5 days of initiating the antibiotic.
The onset of the interaction is rapid; early monitoring allows for further titration before dangerous coagulopathy develops.

Key Concept

Patients stabilized on warfarin who are prescribed highly interacting antibiotics (such as trimethoprim-sulfamethoxazole) require preemptive dose reductions (typically 25% to 50%) and early follow-up INR monitoring (within 3 to 5 days) to prevent life-threatening hemorrhage.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic